Seres Therapeutics (MCRB) announced new translational biomarker results for exploratory endpoints from its SER-155 Phase 1b ...

SunAct Cancer Institute has announced the commencement of Phase 2 clinical trials for Gamma Delta (gd) T-cell therapy, a ...

Celebrate advancements in bone marrow transplantation in India, offering hope and life-saving treatments for patients ...

New SER-155 Phase 1b study biomarker data in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients demonstrate that SER-155 promoted epithelial barrier integrity and decreased ...

Sana Biotechnology has shared early data for its investigational allogeneic cell therapy being studied in one patient with ...

Imugene Limited (ASX:IMU) has hit its first important milestone in 2025, dosing its first Australian patient with its ...

Researchers at Children's Hospital of Philadelphia (CHOP) and the University of Pennsylvania Perelman School of Medicine ...

Roche's strategic changes in drug development and M&A activity may drive future growth, despite recent setbacks in clinical ...

While gene therapy has emerged as a promising alternative for treating beta-thalassemia, hematopoietic stem cell transplantation (HSCT) remains the only widely accessible curative option for this ...

Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.

Our Bureau, Mumbai Tuesday, January 7, 2025, 16:45 Hrs [IST] ...